Highlights Ocugen, Inc.

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 24/01/2026 am IST			5-day change	1st Jan Change
1.660 ^USD	+0.61%		-1.78%	+22.96%

23/01	Ocugen Closes $20.9 Million Registered Direct Offering	MT
21/01	Ocugen Prices $22.5 Million Stock Offering	MT

Highlights

23/01	Ocugen Closes $20.9 Million Registered Direct Offering	MT
15/01	Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration	CI
05/11	Ocugen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
05/11	Tranche Update on Ocugen, Inc.'s Equity Buyback Plan announced on October 9, 2019.	CI
05/11	Biotech firm Ocugen's Q3 revenue beats expectations	RE
18/25/18	Ocugen Inc says on Sept 16, carisma terminates merger agreement with Ocugen	RE
15/25/15	Ocugen Licenses Korean Rights to Gene Therapy OCU400 in $7.5 Million Deal With Kwangdong	MT
15/25/15	Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea	CI
13/25/13	Ocugen Receives European Medicines Agency Committee's Acceptance for OCU410ST Study	MT
13/25/13	Ocugen gets EMA backing on OCU410ST approval pathway for Stargardt gene therapy	RE
13/25/13	Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST--Modifier Gene Therapy for Stargardt Disease	CI
04/25/04	Tranche Update on Ocugen, Inc.'s Equity Buyback Plan announced on October 9, 2019.	CI
02/25/02	Ocugen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
01/25/01	Biotech firm Ocugen's Q2 revenue beats expectations at $1.37 mln	RE
18/25/18	Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST	CI
23/25/23	Carisma Therapeutics to Merge With OrthoCellix in All-Stock Transaction	MT
16/25/16	Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of Ocu410st	CI
05/25/05	Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of Ocu400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea	CI
05/25/05	Ocugen Signs Deal for Korean Rights to Gene Therapy OCU400	MT
27/25/27	Ocugen Announces Rare Pediatric Disease Designation Granted For Ocu410st--Modifier Gene Therapy For The Treatment Of Stargardt Disease	RE
27/25/27	Ocugen, Inc. Announces Rare Pediatric Disease Designation Granted for OC410ST--Modifier Gene Therapy for the Treatment of Stargardt Disease	CI
09/25/09	Ocugen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
09/25/09	Tranche Update on Ocugen, Inc.'s Equity Buyback Plan announced on October 9, 2019.	CI
18/25/18	Ocugen, Inc. Announces Data and Safety Monitoring Board Reviewed Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial	CI
05/25/05	Ocugen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Ocugen, Inc.

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Highlights

Filters